Genevieve Laforet

Genevieve Laforet

Company: Aspa Therapeutics

Job title: Vice President, Clinical Development


Genevieve (Jenny) Laforet is Vice President, Clinical Development at Aspa Therapeutics, an affiliate of BridgeBio, where she leads Aspa’s BBP-812 gene therapy program for Canavan disease. A psychiatrist with a research background in genetic CNS disorders, she has 17 years of industry experience in a variety of scientific/medical affairs and clinical development roles with a focus on rare pediatric neurological diseases.


AAV-Associated Complement Activation in the Clinical Trial Setting 9:15 am

Review of the complement system and pathophysiology of thrombotic microangiopathy (TMA) – broadening our perspective on organ systems at risk Exploring episodes of complement-mediated TMA seen in AAV clinical trials Mechanistic hypotheses regarding TMA risk in different gene therapy settings Practical considerations around TMA surveillance, prophylaxis and managementRead more

day: Day Two

Panel Discussion: Aligning Immunomodulation Regimens with Overall Development Goals 9:00 am

Outlining early your desired downstream immune response to better inform your regimen selection Key considerations in AAV vector types for this selection process Linking patient population characteristics to the regimenRead more

day: Day One

A Hanson Wade Group Company

© Copyright 2023 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.